Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

1st evidence that nuclear transplantation (’therapeutic cloning’) can eliminate tissue rejection

03.06.2002


Heart ’patches’ and functioning kidney units cloned in cows



Advanced Cell Technology, Inc. (ACT) reported today that nuclear transplantation can be used to generate functional immune-compatible tissues. The research, which will appear in the July issue (cover story) of Nature Biotechnology, by ACT and its collaborators, provides the first experimental evidence that it may be possible to use cloning to generate medically important tissues and eliminate tissue rejection. Heart ’patches’ and miniature kidneys engineered from cloned cells were successfully tested in a large-animal model, the cow, which has a sophisticated immune system similar to that of humans.
"These results bode well for the future of human therapeutic cloning," said Robert Lanza, Vice President of Medical & Scientific Development at ACT, and lead author of the study. "Cloning could theoretically provide a limitless supply of cells and organs for any type of regenerative therapy. Before now, therapeutic cloning as a means of preventing rejection was criticized by some as being purely theoretical – just an idea. This study furnishes the first scientific evidence that cloned tissues can be transplanted back into animals without being destroyed by the body’s immune system. The use in medicine to generate immune-compatible cells using cloning would overcome one of the major scientific challenges in transplantation medicine - namely, the problem of organ and tissue rejection."

The goal of nuclear transplantation is to clone genetically matched cells and organs for transplantation into patients suffering from a wide range of disorders that result from tissue loss or dysfunction. In addition to patients with heart, lung, liver and/or kidney disease, millions more suffer from diabetes, arthritis, AIDS, strokes, cancer and other diseases that may one day be treatable using this technology. It has been estimated that by the year 2010 over 2 million patients will suffer from end-stage kidney disease alone, at an aggregate cost of over $1 trillion dollars during the coming decade.



Although nuclear transplantation could theoretically be used to generate immune-compatible cells and tissues for these patients, numerous studies have shown that animals produced by cloning inherit the DNA in their mitochondria (the organelles that supply energy to the cell) entirely or in part from the recipient egg and not the donor cell. The presence of these foreign genes raises the question whether ’non-self’ proteins in cloned cells could lead to rejection after transplantation and defeat the main objective of the procedure. The Nature Biotechnology paper reports that cloned cells were not rejected in cattle despite the presence of the foreign mitochondrial DNA. The immune system in cattle is relatively complex; therefore, these "preclinical" studies suggest human applications may be possible.

In addition to creating skeletal muscle and heart ’patches,’ nuclear transplantation was used to generate immune-compatible kidney units with the ability to excrete toxic metabolic waste products through a urinelike fluid. The renal units not only survived and functioned as kidneys, but immunological studies carried out both in the transplanted animals and in the laboratory confirmed that there was no rejection response to the cloned tissues.

"This was a study to investigate how the immune system would deal with cloned tissue in an animal model," said Michael D. West, President & C.E.O. at ACT and an author on the paper. "In such an animal model, we judged it appropriate to produce cloned bovine fetuses to generate the needed cells. In the case of human medical applications, we are strongly advocating that the technology should only be used to clone human embryonic stem cells not an actual pregnancy. We, therefore, strongly support Senate Bill S. 2439 promoted by Senators Kennedy, Feinstein, Hatch and Specter that would protect the life-saving uses of cloning technology while banning its abuse in cloning a human fetus or child."


###
The researchers of the paper from Advanced Cell Technology, collaborated with scientists from Harvard Medical School and Children’s Hospital, Boston; the Mayo Clinic, Rochester, Minnesota; and the University of Miami School of Medicine, Miami, Florida. The paper’s other authors are Catherine Blackwell of ACT; Anthony Atala, Hoyun Chung, James J. Yoo, Gunter Schuch, and Shay Soker of Children’s Hospital; Peter J. Wettstein, Nancy Borson, and Erik Hofmeister of the Mayo Clinic; and Carlos T. Moraes of the University of Miami School of Medicine.

Advanced Cell Technology is a biotechnology company focused on discovering and commercializing the applications of cloning technology in human medicine and animal science.

Robert Lanza | EurekAlert
Further information:
http://www.advancedcell.com

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>